Peter Waldman of Bloomberg reports the NIH and the FBI are targeting ethnic Chinese scientists, including those that are U.S. citizens, searching for a cancer cure. Bloomberg discusses what happened to Xifeng Wu.
Cancer research is globalized with researchers around the world sharing and pooling data and ideas to collaboratively study a disease that kills 10 million annually. International collaborations represent a core underpinning of programs everywhere, including an intrinsic part of the U.S. National Cancer Institute’s Moonshot program, the government’s $1 billion blitz to double the pace of treatment discoveries by 2022. One of the program’s tag lines: “Cancer knows no borders.”
Except, it turns out, the borders involving China. Recently, an award winning epidemiologist, Xifeng Wu, quietly resigned from her position at the center for Public Health and Translational Genomics at the University of Texas MD Anderson Cancer Center after a three-month investigation into her professional connections in China.
Her resignation and others are the result of a Trump administration drive to counter Chinese influence at U.S. research institutions.
Follow the link below to reach this entire Bloomberg Business Week story. For researchers, it is important to understand how politics and national interests can intermingle in ways that could subvert scientific progress.